TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
DNLI

Denali Therapeutics Inc

Healthcare · Biotechnology

20.50$ +0.0% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Denali Therapeutics Inc (DNLI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,158 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet DNLI
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– 271 231 231 210 487 614 572 544 662 677 638 603 553 696 647 1,070 1,604 1,548 1,510 1,450 1,404 1,321 1,292 1,228 1,460 1,409 1,306 1,237 1,154 1,581 1,503 1,454 1,374 1,271 1,166 1,056 1,145 1,266 1,158
– 182 178 189 188 410 377 377 383 481 500 496 494 430 605 559 971 1,496 1,432 1,342 1,056 897 988 1,115 1,139 1,372 1,325 1,224 1,143 1,064 974 928 869 864 879 935 883 901 1,023 754
– 40 -178 41 36 218 44 33 44 77 40 63 83 79 208 137 351 507 435 486 395 293 105 155 119 218 68 132 148 127 61 75 91 175 57 141 91 205 388 202
– 178 178 187 186 406 373 373 375 464 485 479 479 415 587 550 961 1,470 1,413 1,309 1,039 865 958 1,069 1,106 1,336 1,288 1,191 1,109 1,035 937 896 837 832 818 899 848 868 988 710
– 0.4 – – – 0.5 – 0.5 – 8.5 8.5 – – – – – – 5.7 2.5 17 1.2 1.2 – 0.4 – 9.3 3.2 3.4 – 3.4 1.9 1.4 – 2.2 – 1.4 1.9 2.2 1.6 3.9
– -0.4 – – – -0.5 0.0 -0.5 0.0 -8.5 – – – – – – – – – 0.0 – – – – – -5.0 -3.2 -3.4 – 0.0 – – – – – – – – – 4.1
– 15 15 15 15 15 15 13 16 25 71 82 82 81 79 77 42 41 41 72 40 70 38 68 42 75 42 40 – – – – – – – – – – – –
– – – – – – 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
– – – – – – 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – 36 35
– 17 18 11 17 21 75 82 83 115 160 162 165 158 151 145 188 454 443 437 438 442 403 408 416 418 443 119 118 123 126 116 136 144 149 139 129 131 340 323
– 9.1 11 11 10 14 17 31 32 33 43 47 47 45 48 58 105 72 55 51 54 378 341 348 361 364 391 69 71 78 83 75 87 102 92 91 90 98 110 90
– – – – – – 7.3 13 15 19 0.8 18 23 3.7 4.1 4.3 4.5 4.7 4.9 5.1 5.3 5.5 5.7 5.9 7.1 7.3 6.5 6.8 7.0 7.3 7.5 7.8 8.0 12 8.6 8.9 9.2 9.5 9.9 –
– 2.0 1.4 1.4 2.3 2.7 1.4 9.2 3.4 1.9 3.7 3.9 2.0 2.6 2.3 1.9 2.8 1.1 1.6 4.2 4.8 4.8 3.4 7.1 7.5 2.8 2.2 8.5 1.2 9.5 12 14 9.6 11 8.5 11 6.7 3.3 40 12
– – – – – – 0.0 0.0 0.0 – 71 – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
– 255 255 213 193 466 539 490 461 547 517 475 438 395 545 502 883 1,151 1,105 1,073 1,012 962 918 884 811 1,042 967 1,187 1,118 1,031 1,455 1,387 1,318 1,230 1,123 1,027 926 1,014 926 835
– -104 -147 -147 -169 -192 -215 -270 -305 -228 -267 -325 -372 -426 -482 -541 -599 -354 -424 -485 -570 -645 -710 -769 -872 -971 -1,081 -897 -997 -1,116 -1,218 -1,317 -1,424 -1,539 -1,672 -1,796 -1,923 -2,052 -2,180 -2,308
6.8 9.0 9.0 68 82 31 90 93 94 98 95 95 96 96 102 106 107 128 121 123 122 122 123 123 123 133 137 141 138 138 149 169 169 170 171 171 172 175 187 187

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?